Nan Fung Trinity HK Ltd. Acquires Shares of 154,522 KalVista Pharmaceuticals, Inc. $KALV

Nan Fung Trinity HK Ltd. bought a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 154,522 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,747,000. Nan Fung Trinity HK Ltd. owned approximately 0.31% of KalVista Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of KALV. Rhumbline Advisers increased its position in KalVista Pharmaceuticals by 3.4% during the first quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company’s stock worth $611,000 after acquiring an additional 1,762 shares during the period. Corebridge Financial Inc. raised its position in shares of KalVista Pharmaceuticals by 12.7% in the first quarter. Corebridge Financial Inc. now owns 19,094 shares of the specialty pharmaceutical company’s stock valued at $220,000 after buying an additional 2,149 shares in the last quarter. MetLife Investment Management LLC boosted its stake in shares of KalVista Pharmaceuticals by 13.2% in the first quarter. MetLife Investment Management LLC now owns 21,688 shares of the specialty pharmaceutical company’s stock valued at $250,000 after buying an additional 2,536 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in KalVista Pharmaceuticals by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock worth $281,000 after buying an additional 2,939 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in KalVista Pharmaceuticals by 2.8% in the 1st quarter. Wellington Management Group LLP now owns 126,268 shares of the specialty pharmaceutical company’s stock valued at $1,457,000 after acquiring an additional 3,405 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th. Citizens Jmp reduced their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday. JMP Securities lifted their price target on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a research note on Friday, September 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.63.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 10,940 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.22, for a total transaction of $144,626.80. Following the completion of the transaction, the chief executive officer owned 386,858 shares of the company’s stock, valued at approximately $5,114,262.76. This trade represents a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 2,942 shares of the business’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total transaction of $38,893.24. Following the completion of the sale, the insider directly owned 119,841 shares in the company, valued at approximately $1,584,298.02. This represents a 2.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 26,856 shares of company stock valued at $374,910 in the last ninety days. Insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Stock Up 5.3%

NASDAQ KALV opened at $11.47 on Wednesday. The company has a market cap of $579.50 million, a price-to-earnings ratio of -2.91 and a beta of -0.04. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $17.28. The business’s fifty day moving average is $12.27 and its 200 day moving average is $12.81.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to the consensus estimate of $6.03 million. On average, research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).